Indicator type;Main activity, secondary activity or tool required for...;Total
Companies carrying out R&D in Biotechnology;Total;1.444
Companies carrying out R&D in Biotechnology;Main;629
Companies carrying out R&D in Biotechnology;Secondary;262
Companies carrying out R&D in Biotechnology;Tool required;553
% Companies by type of biotechnology used: Genetic Code;Total;30,7
% Companies by type of biotechnology used: Genetic Code;Main;39,9
% Companies by type of biotechnology used: Genetic Code;Secondary;25,7
% Companies by type of biotechnology used: Genetic Code;Tool required;22,5
% Companies by type of biotechnology used: Functional Units;Total;37,6
% Companies by type of biotechnology used: Functional Units;Main;46,4
% Companies by type of biotechnology used: Functional Units;Secondary;39,8
% Companies by type of biotechnology used: Functional Units;Tool required;26,5
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;21,3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Main;26,3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Secondary;20
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Tool required;16,2
% Companies by type of biotechnology used: Bioprocesses;Total;50,9
% Companies by type of biotechnology used: Bioprocesses;Main;42,3
% Companies by type of biotechnology used: Bioprocesses;Secondary;57
% Companies by type of biotechnology used: Bioprocesses;Tool required;58
% Companies by type of biotechnology used: Subcellular Organisms;Total;8,1
% Companies by type of biotechnology used: Subcellular Organisms;Main;11,6
% Companies by type of biotechnology used: Subcellular Organisms;Secondary;5,5
% Companies by type of biotechnology used: Subcellular Organisms;Tool required;5,2
% Companies by type of biotechnology used: Bioinformatics;Total;22,6
% Companies by type of biotechnology used: Bioinformatics;Main;32,3
% Companies by type of biotechnology used: Bioinformatics;Secondary;21
% Companies by type of biotechnology used: Bioinformatics;Tool required;12,5
% Companies by type of biotechnology used: Nanobiotechnology;Total;9,8
% Companies by type of biotechnology used: Nanobiotechnology;Main;14,5
% Companies by type of biotechnology used: Nanobiotechnology;Secondary;10,1
% Companies by type of biotechnology used: Nanobiotechnology;Tool required;4,4
% Companies by type of biotechnology used: Other;Total;16,9
% Companies by type of biotechnology used: Other;Main;18,1
% Companies by type of biotechnology used: Other;Secondary;19,5
% Companies by type of biotechnology used: Other;Tool required;14,2
% Companies by final application areas of biotechnology use: Human Health;Total;44,3
% Companies by final application areas of biotechnology use: Human Health;Main;65
% Companies by final application areas of biotechnology use: Human Health;Secondary;33,6
% Companies by final application areas of biotechnology use: Human Health;Tool required;25,9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Total;15,8
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Main;16,9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Secondary;18
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Tool required;13,5
% Companies by final application areas of biotechnology use: Food Products;Total;30,7
% Companies by final application areas of biotechnology use: Food Products;Main;24,8
% Companies by final application areas of biotechnology use: Food Products;Secondary;30,6
% Companies by final application areas of biotechnology use: Food Products;Tool required;37,5
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Total;24,9
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Main;21,3
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Secondary;28,7
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Tool required;27,3
% Companies by final application areas of biotechnology use: Environment;Total;16,9
% Companies by final application areas of biotechnology use: Environment;Main;17,9
% Companies by final application areas of biotechnology use: Environment;Secondary;20,5
% Companies by final application areas of biotechnology use: Environment;Tool required;14,2
% Companies by final application areas of biotechnology use: Industry;Total;12,6
% Companies by final application areas of biotechnology use: Industry;Main;13,1
% Companies by final application areas of biotechnology use: Industry;Secondary;15,9
% Companies by final application areas of biotechnology use: Industry;Tool required;10,4
R&D personnel in Biotechnology (PP);Total;17.743
R&D personnel in Biotechnology (PP);Main;8.842
R&D personnel in Biotechnology (PP);Secondary;3.407
R&D personnel in Biotechnology (PP);Tool required;5.494
R&D personnel in Biotechnology (PP): Research personnel;Total;9.445
R&D personnel in Biotechnology (PP): Research personnel;Main;5.239
R&D personnel in Biotechnology (PP): Research personnel;Secondary;1.814
R&D personnel in Biotechnology (PP): Research personnel;Tool required;2.392
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;8.298
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Main;3.603
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Secondary;1.594
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Tool required;3.101
R&D personnel in Biotechnology (PP). Women;Total;9.907
R&D personnel in Biotechnology (PP). Women;Main;5.154
R&D personnel in Biotechnology (PP). Women;Secondary;1.970
R&D personnel in Biotechnology (PP). Women;Tool required;2.782
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;5.104
R&D personnel in Biotechnology (PP). Women: Research personnel;Main;2.942
R&D personnel in Biotechnology (PP). Women: Research personnel;Secondary;1.011
R&D personnel in Biotechnology (PP). Women: Research personnel;Tool required;1.151
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;4.802
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Main;2.212
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Secondary;959
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Tool required;1.632
R&D personnel in Biotechnology (FTE);Total;12.993,4
R&D personnel in Biotechnology (FTE);Main;7.060,1
R&D personnel in Biotechnology (FTE);Secondary;2.147,6
R&D personnel in Biotechnology (FTE);Tool required;3.785,7
R&D personnel in Biotechnology (FTE): Research personnel;Total;7.069,9
R&D personnel in Biotechnology (FTE): Research personnel;Main;4.263,3
R&D personnel in Biotechnology (FTE): Research personnel;Secondary;1.145,5
R&D personnel in Biotechnology (FTE): Research personnel;Tool required;1.661,1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;5.923,6
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Main;2.796,8
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Secondary;1.002,1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Tool required;2.124,7
R&D personnel in Biotechnology (FTE). Women;Total;7.471,8
R&D personnel in Biotechnology (FTE). Women;Main;4.169,3
R&D personnel in Biotechnology (FTE). Women;Secondary;1.295,3
R&D personnel in Biotechnology (FTE). Women;Tool required;2.007,3
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;3.870,1
R&D personnel in Biotechnology (FTE). Women: Research personnel;Main;2.420,4
R&D personnel in Biotechnology (FTE). Women: Research personnel;Secondary;630,8
R&D personnel in Biotechnology (FTE). Women: Research personnel;Tool required;819
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3.601,6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Main;1.748,9
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Secondary;664,5
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Tool required;1.188,2
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;1.223.801
Expenditure on internal R&D in Biotechnology (thousands of euros);Main;670.507
Expenditure on internal R&D in Biotechnology (thousands of euros);Secondary;216.401
Expenditure on internal R&D in Biotechnology (thousands of euros);Tool required;336.893
1) By type of expenditure: Current expenditure;Total;1.108.189
1) By type of expenditure: Current expenditure;Main;604.206
1) By type of expenditure: Current expenditure;Secondary;191.555
1) By type of expenditure: Current expenditure;Tool required;312.429
1.1) Labour expenditure of research personnel;Total;360.922
1.1) Labour expenditure of research personnel;Main;207.759
1.1) Labour expenditure of research personnel;Secondary;64.211
1.1) Labour expenditure of research personnel;Tool required;88.953
1.2) Labour expenditure of technical and auxiliary personnel;Total;220.540
1.2) Labour expenditure of technical and auxiliary personnel;Main;104.553
1.2) Labour expenditure of technical and auxiliary personnel;Secondary;29.638
1.2) Labour expenditure of technical and auxiliary personnel;Tool required;86.349
1.3) Other current expenditure;Total;526.727
1.3) Other current expenditure;Main;291.895
1.3) Other current expenditure;Secondary;97.706
1.3) Other current expenditure;Tool required;137.126
2) By type of expenditure: Capital expenditure;Total;115.612
2) By type of expenditure: Capital expenditure;Main;66.301
2) By type of expenditure: Capital expenditure;Secondary;24.847
2) By type of expenditure: Capital expenditure;Tool required;24.464
2.1) Land and buildings;Total;16.843
2.1) Land and buildings;Main;12.566
2.1) Land and buildings;Secondary;799
2.1) Land and buildings;Tool required;3.478
2.2) Equipment and tools;Total;63.527
2.2) Equipment and tools;Main;33.190
2.2) Equipment and tools;Secondary;12.906
2.2) Equipment and tools;Tool required;17.431
2.3) Acquisition of specific R&D software;Total;3.959
2.3) Acquisition of specific R&D software;Main;2.511
2.3) Acquisition of specific R&D software;Secondary;548
2.3) Acquisition of specific R&D software;Tool required;900
2.4) Other R&D-specific IP products;Total;31.284
2.4) Other R&D-specific IP products;Main;18.033
2.4) Other R&D-specific IP products;Secondary;10.594
2.4) Other R&D-specific IP products;Tool required;2.656
1.1) By origin of funds: Own funds;Total;860.603
1.1) By origin of funds: Own funds;Main;442.509
1.1) By origin of funds: Own funds;Secondary;148.111
1.1) By origin of funds: Own funds;Tool required;269.983
1.2) By origin of funds: Funds from the Business sector;Total;128.002
1.2) By origin of funds: Funds from the Business sector;Main;86.860
1.2) By origin of funds: Funds from the Business sector;Secondary;21.937
1.2) By origin of funds: Funds from the Business sector;Tool required;19.205
1.3) By origin of funds: Funds from the Public Administration sector;Total;119.498
1.3) By origin of funds: Funds from the Public Administration sector;Main;69.092
1.3) By origin of funds: Funds from the Public Administration sector;Secondary;24.659
1.3) By origin of funds: Funds from the Public Administration sector;Tool required;25.748
1.4) By origin of funds: Funds from the Higher Education sector;Total;647
1.4) By origin of funds: Funds from the Higher Education sector;Main;620
1.4) By origin of funds: Funds from the Higher Education sector;Secondary;0
1.4) By origin of funds: Funds from the Higher Education sector;Tool required;28
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;12.986
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Main;9.058
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Secondary;0
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Tool required;3.927
1.6) By origin of funds: Funds from the rest of the world;Total;102.065
1.6) By origin of funds: Funds from the rest of the world;Main;62.369
1.6) By origin of funds: Funds from the rest of the world;Secondary;21.694
1.6) By origin of funds: Funds from the rest of the world;Tool required;18.002
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;123.396
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Main;113.418
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Secondary;5.801
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Tool required;4.177
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;88.985
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Main;80.703
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Secondary;4.777
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Tool required;3.505
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;34.412
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Main;32.714
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Secondary;1.024
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Tool required;673
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;39,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Main;50,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Secondary;36,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Tool required;29,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;15,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Main;13,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Secondary;19,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Tool required;15,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;22,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Main;24
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Secondary;21,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Tool required;20,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;12,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Main;10,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Secondary;15,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Tool required;11,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;17,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Main;17,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Secondary;21,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Tool required;14,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;17,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Main;20,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Secondary;20,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Tool required;13,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;16
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Main;17,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Secondary;18,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Tool required;12,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;41,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Main;46,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Secondary;41,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Tool required;35,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;50,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Main;57,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Secondary;50,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Tool required;42
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;20,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Main;21,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Secondary;22,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Tool required;17
% Companies with international revenues related to biotechnology activities;Total;22,7
% Companies with international revenues related to biotechnology activities;Main;30,6
% Companies with international revenues related to biotechnology activities;Secondary;21,8
% Companies with international revenues related to biotechnology activities;Tool required;14,2
% Companies representing international revenues related to biotechnology activities;Total;2,1
% Companies representing international revenues related to biotechnology activities;Main;13,2
% Companies representing international revenues related to biotechnology activities;Secondary;0,4
% Companies representing international revenues related to biotechnology activities;Tool required;2,2
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Total;60,6
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Main;62,9
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Secondary;52,4
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Tool required;59,7
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Total;39,4
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Main;37,1
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Secondary;47,6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Tool required;40,3
% International revenues related to biotechnology activities by classification: International trade in goods and services;Total;87,8
% International revenues related to biotechnology activities by classification: International trade in goods and services;Main;79,4
% International revenues related to biotechnology activities by classification: International trade in goods and services;Secondary;98
% International revenues related to biotechnology activities by classification: International trade in goods and services;Tool required;99,1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;10,1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Main;17,6
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Secondary;0
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Tool required;0
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Total;1,4
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Main;1,7
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Secondary;2
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Tool required;0,7
% International revenues related to biotechnology activities by classification: Other;Total;0,8
% International revenues related to biotechnology activities by classification: Other;Main;1,2
% International revenues related to biotechnology activities by classification: Other;Secondary;0
% International revenues related to biotechnology activities by classification: Other;Tool required;0,2